Form 4: Twist Bioscience Executive Sells Shares to Cover Tax Obligations

A Twist Bioscience executive sold 144 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Dennis Cho, a Senior Vice President at Twist Bioscience, sold 144 shares of common stock on January 3, 2025.
• The sale was executed at a price of $45.5911 per share.
• This transaction was not a discretionary trade but was mandated by the company's equity incentive plan to cover tax withholding obligations.
• Following the transaction, Mr. Cho directly owns 113,027 shares of Twist Bioscience stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This is a routine transaction related to executive compensation and is common in publicly traded companies. It does not indicate any change in the company's performance or outlook.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are common among executives at publicly traded companies, such as those in the biotechnology sector like Illumina or Regeneron, where equity compensation is a significant part of overall pay.
• These transactions are typically disclosed via Form 4 filings with the SEC, which is standard practice for all publicly traded companies in the US.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Twist Bioscience, stock sale, insider trading, tax obligations, restricted stock units, equity incentive plan, Form 4